Q2 2025 · 13F-HR
Foresite Capital Management VI LLCholdings as filed
Filed 2025-08-12 · accession 0001104659-25-076821
$177.9M
Reported value
20
Positions
2025-06-30
Period end
The Brief · Foresite Capital Management VI LLC · Q2 2025
AI · grounded in 13F
Foresite Capital Management VI LLC established a new position in CG Oncology, Inc. CGON valued at $57.8M. The fund also initiated new stakes in Centessa Pharmaceuticals Inc CNTA for $16.5M and Akero Therapeutics Inc AKRO for $13.1M. Additional new positions include Alumis Inc ALMS, Rapt Therapeutics Inc RAPT, and Bicara Therapeutics Inc BCAX.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG Oncology, Inc. | $57.8M | 32.5% | 2,221,474 | Common | SOLE |
| 152309100 | CNTA | Centessa Pharmaceuticals Inc | $16.5M | 9.26% | 1,253,379 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $13.1M | 7.35% | 244,900 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc | $12.7M | 7.16% | 4,247,670 | Common | SOLE |
| 75382E208 | RAPT | Rapt Therapeutics Inc | $12.5M | 7.03% | 1,562,500 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc | $8.8M | 4.96% | 949,260 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $7.7M | 4.31% | 585,000 | Common | SOLE |
| 433313103 | HNGE | Hinge Health Inc | $7.0M | 3.93% | 135,000 | Common | SOLE |
| 221015100 | CRVS | Corvus Pharmaceuticals Inc | $6.9M | 3.89% | 1,731,233 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics Inc | $6.4M | 3.59% | 146,332 | Common | SOLE |
| 92337C203 | VSTM | Verastem Inc | $5.3M | 2.98% | 1,276,520 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $5.0M | 2.82% | 160,000 | Common | SOLE |
| 230031106 | CGEM | Cullinan Therapeutics Inc | $4.5M | 2.51% | 594,025 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc | $4.4M | 2.45% | 210,000 | Common | SOLE |
| 019770106 | ALLO | Allogene Therapeutics Inc | $3.2M | 1.83% | 2,875,357 | Common | SOLE |
| 45166A102 | IDYA | Ideaya Biosciences Inc | $3.0M | 1.71% | 144,468 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $1.1M | 0.64% | 40,000 | Common | SOLE |
| 00773J202 | SYRE | Spyre Therapeutics Inc | $1.0M | 0.59% | 70,000 | Common | SOLE |
| G1933S101 | CASIF | Casi Pharmaceuticals Inc | $928,803 | 0.52% | 787,121 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics, Inc | $27,597 | 0.02% | 1,974 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.